Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 210
HOS-215071 · Präparat HOS-155350
MedDRA system Very common adverse Common adverse Uncommon organ classes reactions reactions adverse reactions Infections and Infection (G3/4: 6.3%); infestations Neutropenic infection Neoplasms benign, Cancer pain (G3/4: 0.6%) malignant and unspecified (incl cysts and polyps) Blood and lymphatic Neutropenia Febrile neutropenia system disorders (G3/4: 76.3%); Anaemia (G3/4: 9.2%); Thrombocytopenia (G3/4: 5.2%) Immune system Hypersensitivity (no disorders severe) Metabolism and Anorexia (G3/4: 0.6%) nutrition disorders Nervous system Dysgeusia/Parosmia; Dizziness disorders ia; Peripheral sensory neuropathy (G3/4: 0.6%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage b2e2cb30b735fc08d90628044b6640ad4d0a6a3f63db81e1c8ae0845380459e1 · Zeichen 42472–43560 im Abschnitt